Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol

This publication has 16 references indexed in Scilit:

• Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive
  Contraception, 2005
• Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy
  Archives of internal medicine (1960), 2004
• Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2003
• Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill
  Published by Wiley ,2002
• A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra™/Evra™)
  Fertility and Sterility, 2002
• Oral Contraceptives and the Risk of Venous Thrombosis
  New England Journal of Medicine, 2001
• Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis
  BMJ, 2000
• Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
  The Lancet, 1995
• Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
  The Lancet, 1995
• Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study
  The Lancet, 1995